| Literature DB >> 31695472 |
Carole A Samango-Sprouse1,2,3, Debra R Counts4, Selena L Tran3, Patricia C Lasutschinkow3, Grace F Porter3, Andrea L Gropman5,6.
Abstract
47,XXY (Klinefelter syndrome [KS]) is the most common sex chromosomal aneuploidy (1:660), yet, despite this, only 25% of the males are ever diagnosed. Males with 47,XXY present with characteristic symptoms throughout their lifetime with typical physical and neurodevelopmental manifestations focused in growth, cognitive development, endocrine function, and reproduction. Studies have demonstrated that optimal outcomes are dependent on early detection combined with consistent and targeted neurodevelopmental treatment throughout the lifespan. During infancy and into the preschool years, individuals with 47,XXY commonly face deficits in growth and development in the areas of early hormonal, motor, speech, and behavioral development. As they transition into school, the primary neurodevelopmental concerns include language difficulty, executive dysfunction, behavior, and learning and reading deficits. Adults with 47,XXY often present with taller than average height, low levels of fertility, azoospermia, and elevated gonadotropin levels. These presentations may persist from early childhood through adulthood but can be mitigated by appropriate interventions. Early neurodevelopmental and hormonal treatment has been shown to have a minimizing effect on the physical and neurodevelopmental manifestations in individuals with 47,XXY. With innovative and current research studies, the features common to the neurodevelopmental profile of 47,XXY have been further expanded and defined. Further research is necessary to elucidate and understand the relationship between the brain, behavior, and the phenotypic profile of 47,XXY.Entities:
Keywords: 47; Klinefelter syndrome; XXY; hormonal treatment; neurodevelopment
Year: 2019 PMID: 31695472 PMCID: PMC6815760 DOI: 10.2147/TACG.S180450
Source DB: PubMed Journal: Appl Clin Genet ISSN: 1178-704X
Figure 1The process of nondisjunction.
Note: Copyright©2017. Morgan & Claypool Life Sciences. Reproduced from Samango-Sprouse C, Gropman AL. X & Y chromosomal variations: hormones, brain development, and neurodevelopmental performance. Colloquium Series Developing Brain. 2017;5(2):i–122.12
Management Of Endocrinology Issues
| Biochemical Abnormalities & Clinical Manifestations | Intervention |
|---|---|
| Lack of neonatal testosterone surge | EHT: testosterone 25 mg IM qmonth × 3 |
| Smaller testicular and phallic size | |
| Cryptorchism (congenital or acquired) | Orchiopexy by age 1 year |
| Increased growth/tall stature | Monitor (evaluate if small) |
| Hypergonadotropic hypogonadism | Monitor for rise in LH/FSH starting at age 11 years, begin testosterone replacement when levels rise; prefer topical gel to preserve fertility |
| Low testosterone levels | |
| Delayed/lack of spontaneous puberty | |
| Lack of masculinization | |
| Low muscle mass/ increase fat mass | |
| Progressive testicular failure | |
| Osteoporosis | |
| Increased aromatization of testosterone to estradiol gynecomastia | Anastrozole 1 mg qd (if > Tanner 3 may need breast reduction surgery) |
| Azoospermia | Sperm collection age 16–20 years ideally |
| Infertility | |
| Increased risk for germ cell tumors | Monitor LDH, AFP, and HCG |
| Increased risk for breast cancer | |
| Increased risk for Type 2 diabetes, blood clots, autoimmune disorders | Monitor |
Abbreviations: EHT, early hormonal therapy; LH/FSH, luteinizing and follicle-stimulating hormones; LDH, lactate dehydrogenase; AFP, alpha-fetoprotein; HCG, human chorionic gonadotropin.
Management Of Neurodevelopmental Concerns Throughout The Lifespan
| Infancy | Toddlers | School-Aged | Adolescence | Management | |
|---|---|---|---|---|---|
| Latching difficulties | X | Lactation specialist | |||
| Oral motor weakness | X | X | Speech and language specialist (SLP) | ||
| Speech delays | X | X | X | X | SLP |
| Truncal hypotonia | X | X | X | X | Physical therapy (PT) |
| Positional torticollis | X | X | PT | ||
| Plagiocephaly | X | X | PT | ||
| Pes planus | X | X | X | Orthotic inserts | |
| Dysgraphia | X | X | OT | ||
| Reading disorder | X | X | Neurodevelopmental evaluation | ||
| Fitness | X | X | 30 mins running/walking 4X/week | ||
| ADHD | X | X | Neurodevelopmental evaluation | ||
| Anxiety | X | X | Cognitive behavioral therapy | ||
| Behavioral problems | X | X | Pediatrician/psychiatrist | ||
| Kyphosis | X | Orthopedic evaluation | |||
| Scoliosis | X | Orthopedic evaluation | |||
| Leg length discrepancy | X | X | Orthopedic evaluation |
Abbreviations: SLP, speech and language specialist; OT, occupational therapist; PT, physical therapy; TRT, testosterone replacement therapy.